CYTO Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

$1.50  -0.01 (-0.66%)
As of 12/06/2021 16:00:01 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Bermuda
Country of incorporation:  Bermuda
IPO date:  08/06/2014
Outstanding shares:  12,869,587
Average volume:  10,728,617
Market cap:   $19,433,076
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
ISIN:        BMG0360L1000
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.02
PS ratio:   0.00
Return on equity:   -72.85%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy